Skip to Content
Living with relapsing MS? Don’t miss these free events >>

Ethchlorvynol Disease Interactions

There are 8 disease interactions with ethchlorvynol:

Major

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Alcohol Intox

Severe Potential Hazard, High plausibility

Applies to: Acute Alcohol Intoxication, Alcoholism

Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs. The central nervous system depressant effects of these agents may be additive with those of alcohol. Severe respiratory depression and death may occur. Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.

References

  1. "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca, Plattsburg, NY.
  3. "Product Information. Equanil (meprobamate)." Wallace Laboratories, Cranbury, NJ.
View all 5 references
Major

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Ambien (zolpidem)." Searle, Skokie, IL.
  3. "Product Information. Equanil (meprobamate)." Wallace Laboratories, Cranbury, NJ.
View all 5 references
Major

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Drug Dependence

Severe Potential Hazard, High plausibility

Applies to: Alcoholism, Drug Abuse/Dependence

Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms. In patients who have developed tolerance, overdosage can still produce respiratory depression and death. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible. Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents. In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients. After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.

References

  1. Gericke CA, Ludolph AC "Chronic abuse of zolpidem." JAMA 272 (1994): 1721-2
  2. Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E "Tolerance and withdrawal with zolpidem." Lancet 342 (1993): 374-5
  3. "Product Information. Ambien (zolpidem)." Searle, Skokie, IL.
View all 7 references
Major

Ethchlorvynol (Includes Ethchlorvynol) ↔ Porphyria

Severe Potential Hazard, High plausibility

Applies to: Porphyria

The use of ethchlorvynol is contraindicated in patients with a history of porphyria. Ethchlorvynol has been reported to precipitate acute attacks of porphyria in susceptible patients.

References

  1. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
Major

Ethchlorvynol (Includes Ethchlorvynol) ↔ Renal/Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease, Renal Dysfunction

Ethchlorvynol is thought to be metabolized by the liver and subsequently excreted in the urine, primarily as metabolites. Patients with renal and/or liver disease may be at greater risk for adverse effects from ethchlorvynol, including central nervous system and respiratory depression, due to decreased drug clearance. Therapy with ethchlorvynol should be administered cautiously in patients with impaired renal and/or hepatic function. In one study, patients with renal impairment experienced excessive drowsiness following repeated dosing of the drug, presumably due to its accumulation in the plasma.

References

  1. Dawborn JK, Turner A, Pattison G "Ethchlorvynol as a sedative in patients with renal failure." Med J Aust Sept (1972): 702-4
  2. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
Moderate

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Glaucoma

Moderate Potential Hazard, Moderate plausibility

Applies to: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

Moderate

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Moderate

Anxiolytics/Sedatives/Hypnotics (Includes Ethchlorvynol) ↔ Resp Depression

Moderate Potential Hazard, Moderate plausibility

Applies to: Asphyxia, Pulmonary Impairment, Respiratory Arrest, Sleep Apnea

Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are recommended.

References

  1. "Product Information. Ambien (zolpidem)." Searle, Skokie, IL.
  2. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical, Abbott Park, IL.
  3. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca, Plattsburg, NY.
View all 9 references

ethchlorvynol drug Interactions

There are 403 drug interactions with ethchlorvynol

ethchlorvynol alcohol/food Interactions

There is 1 alcohol/food interaction with ethchlorvynol

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide